
Iovance Biotherapeutics Net Income | IOVA
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Iovance Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -391 M | -372 M | -444 M | -396 M | -342 M | -260 M | -198 M | -124 M | -92.1 M | -52.9 M | -27.7 M | -12 M | -25.4 M | -3.31 M | -25.7 M | -1.61 M | -15.8 K | -58.7 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -15.8 K | -444 M | -154 M |
Quarterly Net Income Iovance Biotherapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.3 M | -47.3 M | -79 M | -71.9 M | -91.3 M | -112 M | -116 M | -78.6 M | -83.5 M | -97.1 M | -113 M | -116 M | -114 M | -107 M | -107 M | - | -99.6 M | -99.3 M | -91.6 M | - | -86.1 M | -81.4 M | -75.4 M | -68.4 M | -58.6 M | -63 M | -69.6 M | -63.6 M | -49.5 M | -47.6 M | -37 M | -32.6 M | -33.8 M | -30.7 M | -26.5 M | -25.9 M | -22.1 M | -23.4 M | -20.7 M | -15.7 M | -68.2 M | -11.6 M | -6.88 M | -8.36 M | -7.64 M | -6.37 M | -5.3 M | -4.65 M | -3.01 M | -2.11 M | -2.26 M | - | -9.41 M | -3.43 M | -1.05 M | - | -674 K | -327 K | -5.77 M | - | -5.82 M | -11 M | -564 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -327 K | -116 M | -47.3 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Outlook Therapeutics
OTLK
|
-62.4 M | $ 0.39 | -2.79 % | $ 13.6 M | ||
|
uniQure N.V.
QURE
|
-199 M | $ 19.32 | -4.5 % | $ 1.11 B | ||
|
Ultragenyx Pharmaceutical
RARE
|
-575 M | $ 16.46 | -4.41 % | $ 1.62 B | ||
|
Rafael Holdings
RFL
|
-29.6 M | $ 0.94 | 5.89 % | $ 48.3 M | ||
|
REGENXBIO
RGNX
|
-194 M | $ 7.16 | -0.35 % | $ 369 M | ||
|
Rigel Pharmaceuticals
RIGL
|
367 M | $ 40.05 | -2.78 % | $ 720 M | ||
|
Celsion Corporation
CLSN
|
14.5 M | - | -6.63 % | $ 13.9 M | ||
|
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M | ||
|
Tenax Therapeutics
TENX
|
-52.6 M | $ 1.27 | -8.27 % | $ 49.8 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
3.95 B | $ 514.68 | -1.15 % | $ 132 B | ||
|
Genfit SA
GNFT
|
1.51 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-17 M | - | -13.47 % | $ 169 M | ||
|
SELLAS Life Sciences Group
SLS
|
-26.9 M | $ 13.67 | -8.01 % | $ 1.49 B | ||
|
CureVac N.V.
CVAC
|
162 M | - | - | $ 867 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
-40 M | - | 0.74 % | $ 768 M | ||
|
Abcam plc
ABCM
|
-8.5 M | - | - | $ 4.9 B | ||
|
Rezolute
RZLT
|
-77.6 M | $ 3.92 | -6.69 % | $ 407 M | ||
|
Midatech Pharma plc
MTP
|
-6.38 M | - | -18.52 % | $ 27.3 M | ||
|
Tiziana Life Sciences PLC
TLSA
|
-11.9 M | $ 0.63 | -7.05 % | $ 67.2 M | ||
|
MorphoSys AG
MOR
|
-190 M | - | 2.43 % | $ 254 M | ||
|
Affimed N.V.
AFMD
|
-106 M | - | -34.95 % | $ 21.5 M | ||
|
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-102 M | - | -1.58 % | $ 28.1 M | ||
|
Celyad Oncology SA
CYAD
|
-40.9 M | - | - | $ 12.5 M | ||
|
Seer
SEER
|
-73.6 M | $ 1.34 | -3.25 % | $ 74.5 M | ||
|
Gracell Biotechnologies
GRCL
|
-608 M | - | - | $ 3.37 B | ||
|
Summit Therapeutics
SMMT
|
-1.08 B | $ 9.94 | -6.01 % | $ 7.43 B | ||
|
Shattuck Labs
STTK
|
-48.8 M | $ 4.49 | -1.43 % | $ 312 M | ||
|
Silence Therapeutics plc
SLN
|
-43.3 M | $ 19.81 | 0.08 % | $ 2.81 B | ||
|
Soligenix
SNGX
|
-11.1 M | $ 0.22 | -8.25 % | $ 1.14 M | ||
|
Sanofi
SNY
|
7.85 B | $ 46.51 | 0.97 % | $ 56.8 B | ||
|
Spruce Biosciences
SPRB
|
-39 M | $ 38.02 | -6.11 % | $ 29.1 M | ||
|
Spero Therapeutics
SPRO
|
8.57 M | $ 0.74 | -10.95 % | $ 41.5 M | ||
|
Sarepta Therapeutics
SRPT
|
-713 M | $ 13.34 | -5.86 % | $ 1.34 B | ||
|
Savara
SVRA
|
-119 M | $ 4.28 | -17.95 % | $ 952 M | ||
|
Teligent, Inc.
TLGT
|
-25.1 M | - | -13.85 % | $ 16.1 M | ||
|
Viela Bio, Inc.
VIE
|
-151 M | - | - | $ 2.91 B | ||
|
Sutro Biopharma
STRO
|
-191 M | $ 8.6 | -1.38 % | $ 73.1 M | ||
|
Tarsus Pharmaceuticals
TARS
|
-66 M | $ 72.94 | -6.09 % | $ 3.05 B | ||
|
Supernus Pharmaceuticals
SUPN
|
-38.6 M | $ 36.28 | 1.88 % | $ 2.05 B | ||
|
TG Therapeutics
TGTX
|
447 M | $ 63.39 | -2.3 % | $ 9.15 B | ||
|
Aphria Inc.
APHA
|
-84.6 M | - | -0.45 % | $ 4.87 B | ||
|
Viridian Therapeutics
VRDN
|
-343 M | $ 29.91 | -4.87 % | $ 3.05 B | ||
|
Trevi Therapeutics
TRVI
|
-42.8 M | $ 13.35 | -2.73 % | $ 1.8 B | ||
|
Aerpio Pharmaceuticals, Inc.
ARPO
|
-4.32 M | - | -0.90 % | $ 104 M | ||
|
Chiasma, Inc.
CHMA
|
-74.8 M | - | -6.00 % | $ 238 M | ||
|
vTv Therapeutics
VTVT
|
-27 M | $ 16.0 | -2.2 % | $ 64.2 M | ||
|
Adamas Pharmaceuticals, Inc.
ADMS
|
-57.4 M | - | - | $ 376 M | ||
|
Cellect Biotechnology Ltd.
APOP
|
16.8 M | - | 0.38 % | $ 12.9 M |